Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators

Karl Messlinger¹ · Louis K. Balcziak² · Andrew F. Russo³,⁴

Received: 6 December 2019 / Accepted: 12 February 2020 / Published online: 22 February 2020 © The Author(s) 2020

Abstract
The trigeminal ganglion with its three trigeminal nerve tracts consists mainly of clusters of sensory neurons with their peripheral and central processes. Most neurons are surrounded by satellite glial cells and the axons are wrapped by myelinating and non-myelinating Schwann cells. Trigeminal neurons express various neuropeptides, most notably, calcitonin generelated peptide (CGRP), substance P, and pituitary adenylate cyclase-activating polypeptide (PACAP). Two types of CGRP receptors are expressed in neurons and satellite glia. A variety of other signal molecules like ATP, nitric oxide, cytokines, and neurotrophic factors are released from trigeminal ganglion neurons and signal to neighboring neurons or satellite glial cells, which can signal back to neurons with same or other mediators. This potential cross-talk of signals involves intracellular mechanisms, including gene expression, that can modulate mediators of sensory information, such as neuropeptides, receptors, and neurotrophic factors. From the ganglia cell bodies, which are outside the blood–brain barrier, the mediators are further distributed to peripheral sites and/or to the spinal trigeminal nucleus in the brainstem, where they can affect neural transmission. A major question is how the sensory neurons in the trigeminal ganglion differ from those in the dorsal root ganglion. Despite their functional overlap, there are distinct differences in their ontogeny, gene expression, signaling pathways, and responses to anti-migraine drugs. Consequently, drugs that modulate cross-talk in the trigeminal ganglion can modulate both peripheral and central sensitization, which may potentially be distinct from sensitization mediated in the dorsal root ganglion.

Keywords Trigeminal ganglion · Dorsal root ganglion · Sensory neurons · Satellite glial cells · Neuropeptides · CGRP · Signaling

Overview of the trigeminal ganglion
The trigeminal ganglion is outside the blood–brain barrier (Eftekhari et al. 2015b), which allows substances such as neuropeptides released in the trigeminal ganglion to enter the circulation. The trigeminal ganglion gives rise to three large cranial nerves containing mainly the peripheral axons of pseudo-unipolar primary afferent neurons, the ophthalmic (V1), the maxillary (V2), and the mandibular (V3) nerves; in rodents the latter two form one thick bundle at their origin (Fig. 1a). Results from a retrograde labeling study provided some of the first evidences of cross-excitation from V3 to V1 and V2 within the ganglion, including communication between neurons and satellite glial cells (SGCs) discussed below (Thalakoti et al. 2007; Durham and Garrett 2010; Spray et al. 2019). The central processes of the trigeminal afferents arise from the trigeminal ganglion forming the trigeminal nerve that enters the brainstem at the pontine level. While our focus is on the sensory cell bodies and fibers, there is also a bundle of trigeminal motor fibers, with their somata in the midbrain, that runs through the trigeminal ganglion (Young and Stevens 1979). The trigeminal ganglion consists mainly of primary afferent neurons of the pseudo-unipolar type and glial cells. In human trigeminal ganglion, 20–35,000 neurons and about 100 times more non-neuronal cells have been counted.
The neurons can unequivocally be identified by their nearly round and centrally located nucleus, in which nucleoli and chromatin particle may be visible (Wu et al. 2013). In the rat, the diameters of neurons range from about 10 to 60 µm, with more than 90% small to medium-sized neurons measuring 15–35 µm in diameter (Ambalavanar and Morris 1992; Lennerz et al. 2008). The cell bodies are frequently surrounded by a more or less tight single layer of SGCs that may form a functional unit with the neurons signaling one to the other (Durham and Garrett 2010). In the embryonic trigeminal ganglion, each neuroblast is already accompanied by 2–4 glial cells (Bruska and Woźniak 1991) but the number of SGCs increases by about 20 times in the adult rat trigeminal ganglion, concomitant with the increase in inwardly rectifying potassium channels (Kir4.1), the vesicle docking protein SNAP-25 and the neuropeptide CGRP (Durham and Garrett 2010). The distal and central processes are wrapped by Schwann cells, which form a myelin sheath in Aβ and Aδ fiber neurons. Nonmyelinating Schwann cells are found around processes of C fibers. Surrounding the nerves and in the ganglia are fibroblasts forming collagen fibers, small blood vessels (mainly capillaries) and several types of immune cells such as resident microglia-like macrophages (Glenn et al. 1993). A functional cross-talk between neurons and macrophages via purinergic P2X3 receptors and/or SGCs via P2Y receptors is assumed at least in pathological states like in temporomandibular inflammation (Franceschini et al. 2012; Villa et al. 2010).

Neuropeptide-producing neurons in the trigeminal ganglion

Trigeminal ganglion neurons express a wide range of neuropeptides. The neuropeptides calcitonin gene-related peptide (CGRP) and substance P were first immunohistochemically described in dorsal root ganglion neurons, with broad
overlap in shared secretory vesicles but double the number of vesicles with CGRP immunoreactivity (Wiesenfeld-Hallin et al. 1984). Shortly thereafter CGRP and substance P were localized by immunohistochemistry in trigeminal ganglia of different species (Lee et al. 1985; Hanko et al. 1986; Edvinsson et al. 1989). Trigeminal neuropeptides are still of prominent interest due to their involvement in the generation of primary headaches like migraine and cluster headache (Riesco et al. 2017; Tajti et al. 2015; Ashina et al. 2018). Immunostaining studies have revealed several additional neuropeptides, such as neurokinin A (NK-A), cholecystokinin (CCK), galanin (GAL), somatostatin (SOM), and opioid peptides, in the trigeminal ganglion, which have been comprehensively reviewed (Lazarov 2002; Tajti et al. 2015). Most of the peptide-expressing neurons are small or medium-sized and are thus likely nociceptive neurons with Aδ and C fibers that innervate intracranial structures like the dura mater and cerebral arterial vessels (Mayberg et al. 1984; Schueler et al. 2014). According to more recent data from immunostaining and RT-PCR, further neuropeptides, which can be co-localized with CGRP or substance P, such as enkephalins (Quartu and Del Fiacco 1994), nociceptin (Hou et al. 2003), the growth-associated protein GAP-43 (Del Fiacco et al. 1994), pituitary adenylate-cyclase activating polypeptide (PACAP) (Jansen-Olesen et al. 2014) and angiotensin II (Imboden et al. 2006) are present in the trigeminal ganglion. The ratio of neurons found to produce CGRP and substance P seems to depend on the species and differences in staining, however, there is agreement that CGRP is the most prominent neuropeptide with about 40–50% of CGRP-immunoreactive neurons (Lennerz et al. 2008; Eftekhari et al. 2010) (see Fig. 1b). Regarding the role of substance P, it should be noted that the source of substance P from nociceptors is mainly based on non-human experiments. This may help explain the failure of NK1 receptor antagonists for migraine treatment, whereby substance P release is minor, NK1 receptors in the human meninges that cause plasma extravasation may be lacking, and plasma extravasation, if it occurs, cannot activate nociceptors. As further discussed in the last section, the proportion of CGRP-positive neurons is in the same range as in dorsal root ganglia (Kestell et al. 2015), however, in neurons innervating intracranial blood vessels, CGRP has been found enriched compared to neurons innervating facial skin (O’Connor and van der Kooy 1988). This may be a general principle regarding visceral afferent innervation (Horgan and van der Kooy 1992).

Nociceptive afferents are traditionally grouped into two different populations according to their expression of vaniloid-sensitive transient receptor potential (TRPV1) channels or their isolectin B4 (IB4) binding. The first group containing the peptidergic neurons is sensitive to nerve growth factor (NGF), while the second group is sensitive to glial cell line-derived neurotrophic factor (GDNF) during its development (Vedder et al. 1993; Price et al. 2005). This separation seems not very clear cut, because considerable co-localization of TRPV1 and IB4 binding in primary afferent neurons of rat and mouse, particularly in the rat trigeminal ganglion, has been described based on immunostaining (Price and Flores 2007). Interestingly, in this paper 70% of CGRP-immunoreactive neurons have been found colocalized with TRPV1 immunoreactivity. This was significantly more compared to the dorsal root ganglia and may be one explanation for the dominant role of CGRP as a signaling neuropeptide in the trigeminal system.

Functionally, CGRP release from isolated trigeminal ganglion or trigeminal ganglion cell cultures stimulated by noxious irritants is used as a measure for mass activation of trigeminal ganglion neurons (Durham and Russo 1999; Mason et al. 1984; Bellamy et al. 2006; Eberhardt et al. 2008; Kagnoff et al. 2014), keeping in mind that this signal is predictive only for the peptidergic fraction of neurons. Release experiments from the intact trigeminal ganglion using microdialysis is restricted to smaller molecules like substance P (Neubert et al. 2002), because the CGRP molecule is too large for passing microdialysis membranes. The effective role of neuropeptides like CGRP and substance P as signaling molecules is well established in peripheral tissues. Assuming that neuropeptides can also provide intercellular signaling in the trigeminal ganglion, the existence of neuropeptide receptors is an essential prerequisite.

Neuropeptide receptors in the trigeminal ganglion

CGRP receptors are heteromers, composed of the calcitonin receptor-like receptor (CLR), a seven transmembrane spanning protein, the receptor activity-modifying protein 1 (RAMP1), a single membrane-spanning protein, and the receptor component protein (RCP) an intracellular component (Fig. 1d, e). RAMP proteins are required for the trafficking of CLR from the endoplasmic reticulum to the plasma membrane, and specific RAMPs define the ligand specificity of the calcitonin receptor family (McLatchie et al. 1998). CLR combined with RAMP2 or RAMP3 forms receptors with high affinity for adrenomedullin, another peptide of the calcitonin family (Hendrikse et al. 2019). On the other hand, if RAMP1 is combined with the calcitonin receptor instead of CLR, the amylin-1 receptor is formed, which is discussed below.

In the trigeminal ganglion of several species, neurons of mainly medium sizes and glial cells (Schwann cells and SGCs) have been found to be immunopositive for both CLR and RAMP1 (Lennerz et al. 2008; Eftekhari et al. 2015a) (Fig. 1d, e). There is virtually no overlap of CGRP and
in the trigeminal ganglion of monkey and man. The study confirmed the location of CGRP receptors on neurons and SGCs (Miller et al. 2016).

In addition to the canonical CLR/RAMP1 CGRP receptor, the presence of a second CGRP receptor in the trigeminal ganglion, comprised of the calcitonin receptor (CTR) and RAMP1, is now established (Walker et al. 2015; Henrikse et al. 2019). The CTR/RAMP1 complex was originally identified as an amylin receptor, hence it is called the AMY1 receptor. Interestingly, the expression pattern of AMY1 receptor is suggestive of co-localization with CGRP, as discussed below, although this remains to be demonstrated. AMY1 receptors are also present in vascular smooth muscle based on immunostaining (Walker et al. 2015) and suggested by functional data from cell culture studies (Bohn et al. 2017). CGRP receptor expression in the trigeminal ganglion is possibly involved in signaling mechanisms that may be important for sensitizing mechanisms in facial pain and headache generation. A possible site of action within the trigeminal ganglion is discussed below.

The existence of neurokinin-1 (NK1) receptors, receptors for substance P, has indirectly been shown by functional studies in the rat trigeminal ganglion. The activity of spinal trigeminal neurons with afferent input from inflamed temporomandibular joint and facial skin was decreased by injection of an NK1 receptor antagonist into the trigeminal ganglion (Takeda et al. 2012). However, it is not likely that NK1 receptors in the trigeminal ganglion are crucially involved in the generation of migraine pain, since NK1 receptor antagonists are ineffective in migraine therapy or prevention of migraine (Goldstein et al. 1997, 2001). PACAP binds to the three receptor subtypes of the VIP/PACAP receptor family, VPAC1, VPAC2 and PAC1, immunoreactivity of which was found in small diameter neurons in rat and human trigeminal ganglion (Chaudhary and Baumann 2002; Knutsson and Edvinsson 2002). The receptors are coupled to Gs-proteins inducing the same intracellular pathways as CGRP, PAC1 is additionally Gq-protein coupled (Rubio-Beltrán et al. 2018). Release of PACAP within the trigeminal ganglion could thus initiate communication between neighboring trigeminal sensory neurons.

Evidence for neuropeptide receptors that are linked to inhibitory Gi-proteins has also been found in by immunohistochemistry and in situ hybridization in the trigeminal ganglion. The presence of somatostatin receptors (sst2A) (Ichikawa et al. 2003) and galanin receptors (GALR1) (Suzuki et al. 2002) has thus been shown in small- to medium-sized neurons in the rat trigeminal ganglion. Binding sites for cholecystokinin (CCK) have also been localized in the trigeminal ganglion of different species (Ghilardi et al. 1992). In addition, delta opioid receptor binding sites were observed (Ichikawa et al. 2005) and were upregulated following experimental inflammation of the tooth pulp (Huang et al. 2015). It is unknown if these receptors, which are usually linked to an antinociceptive function, have a local inhibitory role in the trigeminal ganglion.

Other neuropeptides, which may have a signaling function in the trigeminal ganglion, but originate most likely from other sources, are orexins and oxytocin. Orexin receptor (OX1R and OX2R) mRNA has been detected in rat trigeminal ganglion neurons and inhibition of both receptors reduced the expression of downstream proteins associated with sensitization of peripheral nociception in a model of temporomandibular joint inflammation (Cady et al. 2014). Oxytocin receptor immunoreactivity has also been found in rat trigeminal neurons, the majority of which also co-expressed CGRP (Tzabazis et al. 2016). In a recent study oxytocin suppressed neuronal hyperexcitability of trigeminal ganglion neurons after nerve injury. This was mediated by modulation of K+ channels through activation of vasopressin-1-receptors, immunoreactivity for which has also been found in trigeminal ganglion neurons (Kubo et al. 2017).

Receptors for other signal molecules expressed in the trigeminal ganglion

In addition to the variety of neuropeptide receptors in the trigeminal ganglion, multiple receptors for neurotrophic factors and other receptors involved in sensory transduction and transmission have been found expressed on the mRNA level or by immunohistochemistry (Lazarov 2002) or have been found by classical pharmacological approaches. Frequently, cultured trigeminal ganglion cells have been used for studies on sensory transduction or presynaptic mechanisms of neurotransmission, for which the cell soma is used as a model of its peripheral or central ending, respectively. Functional receptors expressed in the ganglion may be involved in intracellular signaling, as will be discussed below.

Receptors for classical neurotransmitters are abundantly expressed in the trigeminal ganglion. Using immunohistochemistry, receptor proteins for all types of glutamate receptors, AMPA, kainite, N-methyl-D-aspartate (NMDA) and metabotropic glutamate receptors (mGluR), have been localized in rat trigeminal ganglion neurons (Quartu et al. 2002; Yang et al. 2009; Sahara et al. 1997), and mGluR proteins have also been found in SGCs (Boye Larsen et al. 2014). Besides their role in neurotransmission, NMDA receptors may functionally interact with transient receptor potential
Expression of subunits of nicotinic (nAchR) and muscarinic acetylcholine receptors (mAchR) has been found on the mRNA level and with immunohistochemistry in rat trigeminal ganglion (Flores et al. 1996; Dussor et al. 2004). Considerable proportions of cultured trigeminal ganglion neurons responding to carbachol and nicotine with calcium transients were found suggesting that both nAchR and mAchR are functional (Shelukhina et al. 2017). This may be important for the idea that parasympathetic nerve fibers signal to trigeminal afferents possibly promoting trigeminal autonomic cephalalgias and migraine characterized by autonomic symptoms (Goadsby 2005; Barbanti et al. 2016).

About 70% of rat trigeminal ganglion neurons have been found to be GABAergic by immunohistochemistry, with various subtypes of GABA receptor subunits identified by RT-PCR and in situ hybridization (Hayasaki et al. 2006). GABA was released by strong depolarizing stimuli (high molecular K+ solution) and Cl− currents recorded in whole cell patch clamping showed that the subunits form functional GABA receptors. The authors discussed a possible GABA-driven inhibition of neurons within the trigeminal ganglion. Glycine receptors were also found in rat trigeminal ganglia using immunohistochemistry (Bae et al. 2016).

Serotonin (5-hydroxytryptamine, 5-HT) binds to several types of G-protein-coupled 5-HT receptors, only the 5-HT3 receptor is a cation channel. Three subtypes of the G-protein-coupled serotonin 1 receptors are targets of antimigraine triptans (5HT1B/1D) or “ditans” like lasmitidan (5HT1F) and have been found by immunohistochemistry in the rat trigeminal ganglion (Classey et al. 2010). Interestingly, there was no difference in receptor density compared to dorsal root ganglia showing that the 5HT1 receptor equipment is not specific for the trigeminal system. However, one caveat is that immunohistochemistry does not necessarily reflect functional receptors. For example, the 5HT1D receptor is held in internal stores and only translocated to the cell surface of dorsal root ganglia neurons following neural stimulation (Ahn and Basbaum 2006). In human trigeminal ganglia, 5-HT1B and 5-HT1D receptor immunoreactivity was found predominantly in medium-sized neurons, colocalized with CGRP, substance P or nitric oxide synthase, confirming a close association of 5-HT1 activation and inhibition of neuropeptide release (Hou et al. 2001).

Purinergic receptors binding ATP and other purines are either G-protein coupled (P2Y) or form cation channels (P2X). Expression of different subtypes of P2X receptors, predominantly P2X2 and P2X3, was described in rat trigeminal ganglion neurons of small and medium size, frequently co-expressed with neuropeptides (Xiang et al. 1998; Staikopoulos et al. 2007; Ambalavanar et al. 2005). P2X3 receptor expression in cultured trigeminal ganglion neurons has been found to be enhanced by CGRP and nerve growth factor (Giniatullin et al. 2008; Simonetti et al. 2008) and functionally downregulated by brain natriuretic peptide (Marchenko-ova et al. 2015). P2X3 receptors may be involved in trigeminal neuropathic and inflammatory pain (Shinoda et al. 2007; Teixeira et al. 2010). Immunohistochemical and functional data suggest that P2Y receptors are not expressed by neurons but rather by glial cells in rodent trigeminal ganglia (Weick et al. 2003). Cell cultures imply a bidirectional signaling between neurons and glia cells via ATP (Suadicani et al. 2010), which seems to be enhanced in Ca(v)2.1 α1 R192Q mutant knock-in mice as a model of familial hemiplegic migraine type 1 (Ceruti et al. 2011). Trigeminal ganglion neurons can release ATP upon noxious chemical stimulation (Neubert et al. 2002) and may thus be involved in purinergic signaling within the ganglion, as discussed later.

Significant proportions of trigeminal ganglion neurons express receptors of the transient receptor potential (TRP) family. TRP receptors form transduction channels in peripheral sensory endings and may also be involved in synaptic transmission at the central afferent terminals (Raisinghani et al. 2011). Immunoreactivity for the TRP vanilloid type 1 receptor channel (TRPV1) was found colocalized with CGRP in most of the trigeminal ganglion neurons (Hou et al. 2001). This nonspecific cation channel can be activated by exogenous substances like capsaicin or reserinoratoxin, noxious heat, acidic pH (pH < 5.3), and different endogenous compounds including membrane-derived lipid metabolites like anandamide (Price et al. 2004). CGRP release from trigeminal ganglia or trigeminal ganglion cell cultures induced by capsaicin is frequently used as a measure for trigeminal activation (Thalakoti et al. 2007; Meng et al. 2009). Another member of the TRP receptor family, the transient receptor potential ankyrin 1 (TRPA1) channel, which is highly colocalized with TRPV1 receptors in trigeminal neurons, is activated by irritating substances like mustard oil and cannabinoids (Salas et al. 2009; Jordt et al. 2004). This receptor channel can also be activated by volatile constituents such as umbellulone of the “headache tree” (Nassini et al. 2012). Its functional role in trigeminal nociception is controversial, because on one hand there is experimental evidence for a cooperative effects with TRPV1 in meningeal afferents (Denner et al. 2016) but on the other hand for a dual nociceptive–antinociceptive effect when recordings were made from spinal trigeminal neurons (Teicher et al. 2017). In addition, TRP channels of the M8 type (TRPM8) are expressed in trigeminal ganglion neurons. The transduction channel TRPM8 is interesting, because genome-wide association studies showed that it may be implicated in migraine (Chasman et al. 2011). In a rat behavioral model of headache, the TRPM8 agonist icilin applied onto the cranial dura mater was shown to produce cutaneous facial and hind paw allodynia that was attenuated by systemic pretreatment with
a TRPM8 antagonist (Burgos-Vega et al. 2016). On the contrary, TRPM8 activation reversed meningeal inflammation-induced lowering of the facial heat pain threshold, and in a trigeminal ganglion cell assay TRPM8 activation inhibited TRPV1 effects, which raised speculations about an antinociceptive activity of TRPM8 in migraine (Kayama et al. 2017). Thus, it seems that TRPM8 activation by exogenous agonists can both aggravate and alleviate headache-related behaviors, possibly depending on stimulation of other pro-nociceptive receptors of meningeal afferents (Dussor and Cao 2016).

Other proton-activated transduction channels identified in trigeminal ganglion neurons are the acid-sensing ion channels (ASICs), predominantly the ASIC3 subtype, which is suggested to contribute to headaches under acidic or inflammatory conditions (Yan et al. 2013). Acidic metabolites released under ischemia as a consequence of cortical spreading depression during the aura phase of migraine have been speculated to contribute to the generation of migraine pain (Dussor 2015). Interestingly, CGRP release from cultured trigeminal ganglion neurons induced by protons (pH 5.5) was blocked by an ASIC3 inhibitor but not by the calcium-binding complex EGTA or the antimigraine drugs onabotulinum toxin A or rizatriptan, suggesting that the H+-evoked CGRP release upon ASIC3 opening is not (alone) controlled by calcium binding proteins usually involved in vesicular exocytosis (Durham and Masterson 2013).

**Intercellular cross-talk within the trigeminal ganglion**

Multiple findings regarding the release of chemical signals from trigeminal ganglion cells, cellular responses to these signals and intracellular mechanisms suggest that an intense cross-talk between different cell types may take place within the ganglion. An important way of communication between neurons and satellite glial cells seems to be established via gap junctions, evidence for which was reported already more than 20 years ago (Thalakoti et al. 2007). Capsaicin injected into the temporomandibular joint induced spreading of True Blue between neuronal cell bodies and adjacent glial cells, concomitant with increased expression of inflammatory proteins in both neurons and glia. Injection of the inflammatory cytokine TNFα and capsaicin into rat facial skin was followed by increased expression of the gap-junction forming protein connexin 26 in trigeminal ganglion neurons and SGCs (Damodaram et al. 2009). Similarly, after inferior alveolar nerve injury mechanical allodynia in the whisker pad was accompanied by an enhanced expression of connexin 43 in trigeminal ganglion SGCs, suggesting that glia activation has significant impact on the excitability of nociceptive trigeminal ganglion neurons (Kaji et al. 2016). Functional gap junctions between cultured mouse trigeminal ganglion neurons and glial cells have also been substantiated by recording bidirectional electrical responses with patch clamp techniques (Spray et al. 2019).

Apart from these direct communication mechanisms, intercellular cross-talk by several mediators released from neurons and SGCs seems to be established. In terms of trigeminal nociception and headache generation, the most relevant possible interplay between trigeminal ganglion cells involves CGRP, which may signal to other neurons as well as SGCs and Schwann cells (Fig. 2). This interaction may stimulate various intracellular metabolic changes through the activation of gene expression (Russell et al. 2014). In dorsal root ganglion cell cultures, immunohistochemical data showed that CGRP, via cAMP increase, can cause phosphorylation of cAMP response element binding (CREB) protein, suggesting that CGRP can regulate its own gene expression by pathways involving protein kinase A and mitogen-activated protein kinase/extracellularly regulated kinase (ERK) (Anderson and Seybold 2004). Similar signaling mechanisms have been demonstrated in the trigeminal system (Zhang et al. 2007; Walker et al. 2017). Autocrine regulation of CGRP transcription has been speculated to occur in cerebellar Purkinje neurons (Edvinsson et al. 2011). While colocalization of CGRP and CGRP receptor elements was very rarely seen in trigeminal ganglion neurons (Eftekhar et al. 2010; Lennerz et al. 2008; Tajti et al. 1999), autocrine regulation cannot be ruled out because of the discovery of a second CGRP receptor and the reported plasticity of RAMP1 expression. With respect to the second receptor, as mentioned earlier, the AMY1 receptor is localized primarily in small and medium diameter trigeminal ganglion neurons (Walker et al. 2015), which is in contrast to localization of the CLR/RAMP1 receptor primarily in larger diameter neurons (Eftekhar et al. 2010; Lennerz et al. 2008).

Apart from autocrine functions, CGRP released from trigeminal ganglion neurons can stimulate surrounding cells leading to an enhancement of ATP-gated purinergic P2Y receptors in SGCs (Ceruti et al. 2011) and P2X3 receptors in other neurons (Giniatullin et al. 2008; Simonetti et al. 2008). Control of the purinergic P2X3 receptor by CGRP is of particular interest since it involves two mechanisms (Simonetti et al. 2008), which could come into play during migraine (Fig. 2). First, CGRP can directly act on neurons to initiate a cAMP-signaling cascade that activates the P2X3 gene. Second, CGRP can indirectly act via activation of the neurotrophin BDNF gene and BDNF release from SGCs, which can then upregulate P2X3 expression in neurons. Like CGRP, BDNF is elevated during migraine (Fischer et al. 2012), suggesting that these two mediators act together in augmenting purinergic receptors in migraine. Whether BDNF or P2X3 receptors then feedback to increase CGRP synthesis is not known, but it seems likely, given that they activate pathways known to increase CGRP gene transcription (Durham and
Nitric oxide (NO), cytokines and BDNF may signal back to neurons as growth factors like brain-derived neurotrophic factor (BDNF).

**Fig. 2** Representation of receptor expression and signaling processes in and between trigeminal ganglion cells. Small neurons (with C-fibers) expressing CGRP may signal to satellite glial cells (SGCs) and to middle-sized neurons (with Aδ or C-fibers) expressing CGRP receptors. CGRP release by Ca$^{2+}$-dependent exocytosis can be induced by activating Ca$^{2+}$-conducting ion channels like TRPA1, for example, by nitroxyln (NO$^-$. Autocrine activation by CGRP may occur via CGRP-binding amylin receptors. CGRP and amylin receptors may activate intracellular cascades involving cAMP response-element binding protein (CREB) or mitogen-activated protein kinase (MAPK) to induce gene expression of purinergic (P2X3) receptor channels in neurons and purinergic (P2Y) receptors in SGCs, enzymes like nitric oxide synthase (NOS), cytokines like tumor necrosis factor (TNFα) as well as growth factors like brain-derived neurotrophic factor (BDNF). Nitric oxide (NO), cytokines and BDNF may signal back to neurons facilitating expression of purinergic receptor channels, CGRP and CGRP receptor components like RAMP1. In addition, ATP released from neurons may activate SGCs and macrophage-like cells (MLC), which can signal back to neurons by cytokines. Many of the gene products like CGRP, CGRP receptor proteins and BDNF can crucially influence neuronal transduction and synaptic transmission, because they are delivered by axonal transport through the neuronal processes to the peripheral and/or central terminals of trigeminal afferents.

In summary, these observations indicate that CGRP could function as a paracrine factor to stimulate nearby glial cells and neurons, which in turn could feedback with signal molecules like NO to further stimulate CGRP synthesis and release. This would generate a perfect scenario of a vicious circle for sensitizing trigeminal ganglion neurons, which may contribute to pain exacerbation, as in migraine. However, it should be emphasized that most of the findings mentioned are from cell cultures, where the natural composition and architecture of the ganglion is lost, and therefore the discussed data are suggestive of possible mechanisms that need to be confirmed in vivo. In that regard, substance P release has been reported not only from cultured trigeminal ganglion neurons (Wang et al. 2016) but also from intact trigeminal ganglia using microdialysis (Neubert et al. 2002). Using this method for measuring CGRP release is limited by the higher molecular weight of this neuropeptide that does not readily pass the microdialysis membranes with sufficient selectivity.
Significance of intraganglionic cross-talk for nociceptive transmission

As mentioned above, data derived from experiments with isolated trigeminal ganglion cells should be interpreted with care when they are used to explain possible mechanisms of sensory transduction or transmission. However, since most of the molecules generated in the cell body are stored in vesicles (Zhao et al. 2011) and delivered by axonal transport to the periphery and/or the central nervous system (Maday et al. 2014), they may be relevant there. CGRP and other neuropeptides are transported to the peripheral terminals, where they are released and induce processes of neurogenic inflammation like arterial dilatation and plasma extravasation (Moskowitz 1993; Williamson et al. 1997). The neuropeptides are also transported to the central terminals, where they act as neuromodulators (Storer et al. 2004; Coste et al. 2008). Different to the neuropeptides, a more or less unidirectional transport can be assumed for CGRP receptor subunits. Confocal immunohistochemistry has shown the RAMP1 receptor subunit co-localized with axonal markers only in the central but not the peripheral processes of rat trigeminal afferents, indicating an unilateral transport into the central terminals (Lennerz et al. 2008), although there are conflicting data regarding this issue (Eftekhari et al. 2013). The CGRP receptor subunits can be integrated into the presynaptic membrane of central trigeminal terminals forming functional presynaptic CGRP receptors. They may be activated by CGRP released from central terminals of other trigeminal afferents to facilitate neurotransmitter release and synaptic transmission (Takhshid et al. 2007).

Similarly, a recent immunohistochemical study identified CGRP receptor subunits at nodes of Ranvier of Aδ fibers adjacent to CGRP-containing C fibers in the ganglia and dura (Edvinsson et al. 2019). Thus, there is a possibility of cross-talk between adjacent fibers as well in cell bodies in the ganglia. Another example is brain-derived neurotrophic factor (BDNF), which is expressed in cultured trigeminal neurons dependent on the presence of CGRP (Buldyrev et al. 2006) (Fig. 2). BDNF can be released from central presynaptic terminals and may act on pre- and postsynaptic tyrosine kinase (TrkB) receptors to facilitate nociceptive transmission (Garraway and Huie 2016).

This scenario is most relevant in the light of recent discussions about the sites of action of monoclonal antibodies, which are assumed to act outside the blood–brain barrier inhibiting CGRP signaling and reducing trigeminal functions involved in migraine (Russo 2015), as reviewed elsewhere (Edvinsson 2015) (DosSantos et al. 2014). In this way, substances that act within the trigeminal ganglion (which is outside the blood–brain barrier) contributing to the intraganglionic cross-talk, as discussed above, can have considerable impact on the peripheral and central functions of nociceptive transduction and transmission, and changes in gene expression or transport of molecules can have consequences for peripheral and central functions.

Comparison of trigeminal and dorsal root ganglia sensory neurons

A fundamental question is how does the trigeminal ganglion differ from the dorsal root ganglion (DRG)? Both ganglia serve similar roles of encoding somatosensory modalities such as pain, touch, temperature and proprioception. However, despite their functional overlap, there are distinct differences in their ontogeny, gene expression, including distribution of CGRP receptors, and responses to antimigraine drugs.

The trigeminal ganglion and the dorsal root ganglia arise from different embryological origins. Sensory neurons in the trigeminal ganglion are from a mixed origin of both cranial neural crest cells and the trigeminal ophthalmic and maxillomandibular placodes (Baker and Bronner-Fraser 2001; Barlow 2002; Pavan and Raible 2012). In contrast, the dorsal root ganglia originate entirely from trunk neural crest progenitor cells. The differentiation potential of neural crest along the rostral–caudal axis (cranial to trunk) is directed in part by expression of HOX homeotic genes and environmental cues, such as morphogens (Le Douarin et al. 2004; Philippidou and Dasen 2013). For the cranial vs trunk choice, the Wnt morphogen directs neural crest
transcription factors that cause rostral–caudal division in the
(Holland and Hogan 1988). Interestingly, the embryonic neurons of the dorsal root ganglia and trigeminal

cells to a trunk fate of sensory neuron progenitors (Hack-
land et al. 2019). Wnt also induces expression of homeobox
transcripts such as the homeobox genes up to embryonic day
15 (Eng et al. 2007). Differential homeobox expression and
activity may partially drive dorsal root ganglion develop-
ment that allows it to have unique expression patterns com-
pared to the trigeminal ganglion.

In the adult trigeminal and dorsal root ganglion neu-
rons, there are unique patterns of expression that mirror
the embryological differences. Using transgenic mice with
GFP expression in only sensory cells, neurons in the DRG
and trigeminal ganglion were separated from non-neuronal
cell types by FACS and analyzed by RNAseq (Lopes et al.
2017). The two different sensory ganglia had almost iden-
tical gene expression with the exception of 63 genes. For
example, the dorsal root ganglion had homeobox transcripts
that were not present in the trigeminal ganglion. Conversely,
the trigeminal ganglion had RNAs encoding vasopressin,
oxytocin and GABA receptor subunits. A similar RNAseq
study focusing on RNAs being actively translated revealed
that the trigeminal ganglion has greater expression of genes
in the PI3K–mTORC1 pathway, while inhibitors of the path-
way were more prominent in the dorsal root ganglion (Megat
et al. 2019). Enhanced expression of PI3K–mTORC1 path-
way genes in the trigeminal ganglion was also confirmed at
the protein level. The enhanced mTOR pathway may help
partially explain why trigeminal neurons have different sen-
sory thresholds compared to dorsal root ganglion neurons.

With respect to CGRP signaling in dorsal root and
trigeminal ganglion, there are some potential differences in
receptor expression, distribution and site of action. Using
immunohistochemistry, in adult trigeminal ganglion neurons
the CGRP receptor components RAMP1 and CLR were pre-
dominantly found in medium-sized cell bodies, presumably
with Aδ fibers, whereas CGRP expression was predomi-
nantly seen in small neurons with unmyelinated C-fibers
(Lennerz et al. 2008; Eftekhari et al. 2010). Thus, trigeminal
ganglion neurons have little or no colocalization of CGRP
and its receptor subunits. In contrast, small diameter dorsal
root ganglion neurons in rats express CGRP and at least
low levels of CLR and RAMP1 colocalized in the cell bod-
ies (Cottrell et al. 2012). However, these differences have
not been compared in head to head tests and so may reflect
differences in tissue extraction, quality of antibodies and
immunostaining protocols.

Likewise, CGRP may act at different presynaptic and
postsynaptic sites when released from the trigeminal and
dorsal root ganglion neurons, although there are conflicting
reports. In the dorsal horn, CLR expression was initially found
predominantly on cell bodies and dendrites of second-order
neurons (Ye et al. 1999). However, subsequent studies found
CGRP receptor subunits to be predominantly presynaptic and
only on a few cell bodies in the dorsal horn (Marvizón et al.
2007; Eftekhar and Edvinsson 2011; Cottrell et al. 2012). In
the spinal trigeminal nucleus, CGRP receptor subunits were
initially identified only on fibers from the trigeminal ganglion,
which indicated an exclusively presynaptic localization of
CGRP receptors. However, a subsequent study using a differ-
cent antibody that recognizes the CLR/RAMP1 complex found
the receptor predominantly on cell bodies and dendrites and
on only some axon terminals (Miller et al. 2016). Hence, it
remains unresolved whether CGRP acts presynaptically and/or
postsynaptically in the spinal dorsal horn and trigeminal
nucleus.

Responses to antimigraine medication may also be a
point of difference between the two neuron populations. The
5HT1b/D receptors for triptans are present on both trigemi-
nal and dorsal root ganglion neurons, yet to date it appears
that triptans are efficacious for only trigeminal and
primary afferents is not known. Another example is a study
in which sumatriptan failed to prevent dorsal root ganglion-
mediated pain responses in rodents with a variety of tests such
as tail flick or the hot pad (Skingle et al. 1990). Finally, a meta-
analysis found that antimigraine medications such as anticon-
vulsants had different effectiveness ratings in pain conditions
such as trigeminal neuralgia or pain due to peripheral nerve
injury (Jensen 2002). This points to asymmetric traits of the
dorsal root ganglia and the trigeminal ganglion for response
to treatments.

Overall, while dorsal root and trigeminal ganglion neurons
are similar sensors of peripheral stimuli, they have different
embryonic origins, transcription patterns, signaling path-
ways, and responses to antimigraine medications. Differences
between the two groups of sensory neurons may provide clues
for selective targeting of CGRP and other targets that modulate
peripheral and central sensitization in pain states.

Acknowledgments Open Access funding provided by Projekt DEAL.
This work was supported in part from NIH NS075599 and Merit Award
1I01RX00210 from the U.S. Department of Veterans Affairs to AFR.
The contents do not represent the views of VA or the U.S. Government.

Open Access This article is licensed under a Creative Commons Attri-
butio 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115:1–4. https://doi.org/10.1016/j.pain.2005.03.008

Ahn AH, Basbaum AI (2006) Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain. J Neurosci 26:8332–8338. https://doi.org/10.1523/JNEUROSCI.1890-06.2006

Ambalavanar R, Morris R (1992) The distribution of binding by isocitcin I-B4 from Grifonia simplicifolia in the trigeminal ganglion and brainstem trigeminal nuclei in the rat. Neuroscience 47:421–429

Ambalavanar R, Moritani M, Dessem D (2005) Trigeminal P2X3 receptor expression differs from dorsal root ganglion and is modulated by deep tissue inflammation. Pain 117:280–291. https://doi.org/10.1016/j.pain.2005.06.029

Andersen LE, Seybold VS (2004) Calcitonin gene-related peptide regulates gene transcription in primary afferent neurons. J Neurochem 91:1417–1429. https://doi.org/10.1111/j.1471-4159.2004.02833.x

Ashina H, Schytz HW, Ashina M (2018) CGRP receptor expression: implications for the control of migraine. Cephalalgia Int J Headache 38:353–360. https://doi.org/10.1080/0333102412684344

Bae JY, Mah W, Rah J-C et al (2016) Expression of glycine receptor alpha 3 in the rat trigeminal ganglia and central boutons in the brainstem. Brain Struct Funct 221:4601–4613. https://doi.org/10.1007/s00429-016-1190-4

Baker CV, Bronner-Fraser M (2001) Vertebrate cranial placodes I. Embryonic induction. Dev Biol 232:1–61. https://doi.org/10.1006/dbio.2001.0156

Barbanti P, Aurilia C, Dall'Armi V et al (2016) The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. Cephalalgia Int J Headache 36:1334–1340. https://doi.org/10.1111/1468-2982.13639

Barlow LA (2002) Cranial nerve development: placodal neurons ride the crest. Curr Biol 12:R171–173. https://doi.org/10.1016/s0960-9822(02)00734-0

Bellamy J, Bowen EJ, Russo AF, Durham PL (2006) Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci 23:2057–2066. https://doi.org/10.1111/j.1460-9568.2006.04742.x

Bohn KJ, Li B, Huang X et al (2017) CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1. Br J Pharmacol 174:1826–1840. https://doi.org/10.1111/bph.13783

Bowen EJ, Schmidt TW, Firm CS et al (2006) Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem 96:65–77. https://doi.org/10.1111/j.1471-4159.2005.03524.x

Boye Larsen D, Ingemann Kristensen G, Pancharingham V et al (2014) Investigating the expression of metabotropic glutamate receptors in trigeminal ganglion neurons and satellite glial cells: implications for craniofacial pain. J Recept Signal Transduct Res 34:261–269. https://doi.org/10.3109/10799893.2014.885049

Bruska M, Wozniak W (1991) Ultrastructure of glial cells in the human fetal trigeminal ganglion. Folia Morphol 50:27–48

Buldyrev I, Tanner NM, Hsieh H et al (2006) Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 99:1338–1350. https://doi.org/10.1111/j.1471-4159.2006.04161.x

Burgos-Vega CC, Ahn DD-U, Bischoff C et al (2016) Meningeal transient receptor potential channel M8 activation causes cutaneous facial and hindpaw allodynia in a preclinical rodent model of headache. Cephalalgia Int J Headache 36:185–193. https://doi.org/10.1111/j.1471-4159.2015.06521.x

Cady RJ, Denson JE, Sullivan LQ, Durham PL (2014) Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization. Neuroscience 269:79–92. https://doi.org/10.1016/j.neuroscience.2014.03.043

Capuano A, De Corato A, Lisi L et al (2009) Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain 5:43. https://doi.org/10.1186/1744-8609-5-43

Ceruti S, Villa G, Fumagalli M et al (2011) Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain. J Neurosci 31:3638–3649. https://doi.org/10.1523/JNEURON.6440-10.2011

Chasman DI, Schürks M, Anttila V et al (2011) Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet 43:695–698. https://doi.org/10.1038/ng.856

Chaudhary P, Baumann TK (2002) Expression of VPAC2 receptor and PAC1 receptor splice variants in the trigeminal ganglion of the adult rat. Brain Res Mol Brain Res 104:137–142

Classey JD, Bartsch T, Goodyear PJ (2010) Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective antimigraine effect of triptans. Brain Res 1361:76–85. https://doi.org/10.1016/j.brainres.2010.09.004

Coste J, Voisin DL, Miracourt LS et al (2008) Dorsal horn NK1-expressing neurons control windup of downstream trigeminal nociceptive neurons. Pain 137:340–351. https://doi.org/10.1016/j.pain.2007.09.017

Cottrell GS, Alemi F, Kirkland JG et al (2012) Localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in human gastrointestinal tract. Peptides 35:202–211. https://doi.org/10.1016/j.peptides.2012.03.020

Csáti A, Edvinsson L, Vécsei L et al (2015) Migraine effect of triptans. Brain Res 1361:76–85. https://doi.org/10.1111/j.1471-4159.2015.03843.x

Damodaram S, Thalakoti S, Freeman SE et al (2009) Tonaberdaribit inhibits trigeminal ganglion neuronal-satellite glial cell signaling. Headache 49:5–20. https://doi.org/10.1111/j.1526-4610.2008.01262.x

Del Fiacco M, Quattro M, Priestley JV et al (1994) GAP-43 persists in adulthood and coexists with SP and CGRP in human trigeminal sensory neurons. NeuroReport 5:2349–2352
Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators

Denner AC, Vogler B, Messlinger K, De Col R (2016) Role of transient receptor potential ankyrin 1 receptors in rodent models of meningeal nociception—experiments in vitro. Eur J Pain Lond Engl. https://doi.org/10.1002/eip.986

Dieterle A, Fischer MJM, Link AS et al (2011) Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia Int J Headache 31:31–42. https://doi.org/10.1177/0333102410375725

Dos Santos MF, Holanda-Afonso RC, Lima RL et al (2014) The role of the blood–brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci. https://doi.org/10.3389/fncel.2014.00302

Durham PL, Garrett FG (2010) Development of functional units within trigeminal ganglia correlates with increased expression of proteins involved in neuron–glia interactions. Neuron Glia Biol 6:171–181. https://doi.org/10.1017/S1740925X10000232

Durham PL, Masterson CG (2013) Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache 53:67–80. https://doi.org/10.1111/j.1526-4610.2012.02262.x

Durham PL, Russo AF (1999) Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19:3423–3429

Durham PL, Russo AF (2003) Stimulation of the calcitonin gene-related peptide enhancer by mitogen-activated protein kinases and repression by an antimigraine drug in trigeminal ganglia neurons. J Neurosci 23:807–815

Dussor G (2015) ASICs as therapeutic targets for migraine. Neuropatharmacology 94:64–71. https://doi.org/10.1016/j.neuropharm.2014.12.015

Dussor GO, Helesic G, Hargreaves KM, Flores CM (2004) Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron. Pain 107:22–32

Dux M, Will C, Vogler B et al (2015) Meningeal blood flow is controlled by H2 S-NO crosstalk activating HNO-TRPA1-CGRP signalling. Br J Pharmacol. https://doi.org/10.1111/bph.13164

Eberhardt M, Hoffmann T, Sauer SK et al (2008) Calcitonin gene-related peptide release from intact isolated dorsal root and trigeminal ganglia. Neuropeptides 42:311–317. https://doi.org/10.1016/j.npep.2008.01.002

Eberhardt M, Dux M, Namer B et al (2014) H2S and NO cooperatively regulate vascular tone by activating a neuroendocrine HNO-TRPA1-CGRP signalling pathway. Nat Commun 5:4381. https://doi.org/10.1038/ncomms5381

Edvinsson L (2015) CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol 80:193–199. https://doi.org/10.1111/bcp.12618

Edvinsson L, Hara H, Uddman R (1989) Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: colocalization with different peptides. J Cereb Blood Flow Metab 9:212–218. https://doi.org/10.1038/jcbfm.1989.31

Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K (2011) Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci 46:333–339. https://doi.org/10.1016/j.mcn.2010.10.005

Edvinsson L, Eftekhari S, Warfvinge K, Krause DN et al (2019) C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signalling at nodes of Ranvier in the trigeminal system. J Headache Pain 20:105. https://doi.org/10.1186/s10194-019-1055-3

Eftekhari S, Edvinsson L (2011) Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal nerve fibres. Acta Neuropathol Commun 53:117–124. https://doi.org/10.1186/1471-2202-12-112

Eftekhari S, Salvatore CA, Calamari A et al (2010) Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169:683–696. https://doi.org/10.1016/j.neuroscience.2010.05.016

Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289–1303. https://doi.org/10.1007/s10194-013-0310-0

Eftekhari S, Gaspar RC, Roberts R et al (2015a) Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence and autoradiography. J Comp Neurol. https://doi.org/10.1002/cne.23828

Eftekhari S, Salvatore CA, Johansson S et al (2015b) Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res 1600:93–109. https://doi.org/10.1016/j.brainres.2014.11.031

Eftekhari S, Gaspar RC, Roberts R et al (2016) Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol 524:90–118. https://doi.org/10.1002/cne.23828

Eng SR, Dykes IM, Lanier J et al (2007) POU-domain factor Brn3a regulates both distinct and common programs of gene expression in the spinal and trigeminal sensory ganglia. Neural Dev 2:3. https://doi.org/10.1186/1749-8104-2-3

Fischer M, Wille G, Klien S et al (2012) Brain-derived neurotrophic factor in primary headaches. J Headache Pain 13:469–475. https://doi.org/10.1007/s10194-012-0454-5

Flores CM, DeCamp RM, Kilo S et al (1996) Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of alpha3beta4a, a novel subtype in the mammalian nervous system. J Neurosci 16:7892–7901

Franceschini A, Nair A, Bele T et al (2012) Functional crosstalk in culture between macrophages and trigeminal sensory neurons of a mouse genetic model of migraine. BMC Neurosci 13:143. https://doi.org/10.1186/1471-2202-13-143

Garraway SM, Huie JR (2016) Spinal Plasticity and behavior: BDNF-induced neuremodulation in uninjured and injured spinal cord. Neural Plast 2016:857201. https://doi.org/10.1155/2016/857201

Ghilardi JR, Allen CJ, Vigna SR et al (1992) Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci 12:4854–4866

Giniatullin R, Nistri A, Fabbretti E (2008) Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol Neurobiol 37:83–90. https://doi.org/10.1007/s12035-008-0820-5

Glenn JA, Sonceau JB, Wynder HJ, Thomas WE (1993) Histochemical evidence for microglia-like macrophages in the rat trigeminal ganglion. J Anat 183(Pt 3):475–481

Goadsby PJ (2005) Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 161:692–695

Goldstein DJ, Wang O, Saper JR et al (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17:102–106. https://doi.org/10.1046/j.1468-2982.2001.00161.x

Goldstein DJ, Offen WW, Klein EG et al (2001) Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia Int J Headache 17:102–106. https://doi.org/10.1046/j.1468-2982.2001.00161.x

Goto T, Iwai H, Kuramoto E, Yamakawa A (2017) Neuropeptides and ATP signaling in the trigeminal ganglion. Jpn Dent Sci Rev 53:117–124. https://doi.org/10.1007/j.jsdr.2017.01.003

Springer
Holland PW, Hogan BL (1988) Spatially restricted patterns of expression of the homeobox-containing gene Hox 2.1. during mouse embryogenesis. Dev Camb Engl 102:159–174

Horgan K, van der Kooy D (1992) Visceral targets specify calcitonin gene-related peptide receptors in the human trigeminal ganglion. Brain Res 909:112–120

Hou M, Uddman R, Tajtj E, Edvinsson L (2003) Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res 964:179–186

Huang J, Lv Y, Fu Y et al (2015) Dynamic regulation of delta-opioid receptor in rat trigeminal ganglion neurons by lipopolysaccharide-induced acute pulpitis. J Endod 41:2014–2020. https://doi.org/10.1016/j.joen.2015.09.011

Ichikawa H, Schulz S, Höllt V, Sugimoto T (2003) The somatostatin sst2A receptor in the rat trigeminal ganglion. Neuroscience 120:807–813

Ichikawa H, Schulz S, Höllt V, Sugimoto T (2005) Delta-opioid receptor-immunoreactive neurons in the rat cranial sensory ganglia. Brain Res 1043:225–230. https://doi.org/10.1016/j.brainres.2005.02.041

Imboden H, Paul J, Nussberger J et al (2009) Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia. Regul Pept 154:23–31. https://doi.org/10.1016/j.regpep.2009.02.002

Jansen-Olesen I, Baun M, Amruttak DV et al (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides 48:53–64. https://doi.org/10.1016/j.npep.2014.01.004

Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain Lond Engl 6(Suppl A):61–68. https://doi.org/10.1006/ejpu.2001.0324

Jord E, Bautista DM, Chuang H-H et al (2004) A local GABAergic system within rat trigeminal ganglion. Eur J Neurosci 23:745–757. https://doi.org/10.1111/j.1460-9568.2004.04020.x

Hendrikse ER, Bower RL, Hay DL, Walker CS (2019) Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia Int J Headache 39:403–419. https://doi.org/10.1177/0333102418765787

Holland PW, Hogan BL (1988) Spatially restricted patterns of expression of the homeobox-containing gene Hox 2.1. during mouse embryogenesis. Dev Camb Engl 102:159–174

Horgan K, van der Kooy D (1992) Visceral targets specify calcitonin gene-related peptide and substance P enrichment in trigeminal afferent projections. J Neurosci 12:1135–1143

Hou M, Kanje M, Longmore J et al (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 909:112–120

Hou M, Uddman R, Tajtj E, Edvinsson L (2003) Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res 964:179–186

Huang J, Lv Y, Fu Y et al (2015) Dynamic regulation of delta-opioid receptor in rat trigeminal ganglion neurons by lipopolysaccharide-induced acute pulpitis. J Endod 41:2014–2020. https://doi.org/10.1016/j.joen.2015.09.011

Ichikawa H, Schulz S, Höllt V, Sugimoto T (2003) The somatostatin sst2A receptor in the rat trigeminal ganglion. Neuroscience 120:807–813

Ichikawa H, Schulz S, Höllt V, Sugimoto T (2005) Delta-opioid receptor-immunoreactive neurons in the rat cranial sensory ganglia. Brain Res 1043:225–230. https://doi.org/10.1016/j.brainres.2005.02.041

Imboden H, Paul J, Nussberger J et al (2009) Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia. Regul Pept 154:23–31. https://doi.org/10.1016/j.regpep.2009.02.002

Jansen-Olesen I, Baun M, Amruttak DV et al (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides 48:53–64. https://doi.org/10.1016/j.npep.2014.01.004

Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain Lond Engl 6(Suppl A):61–68. https://doi.org/10.1006/ejpu.2001.0324

Jord E, Bautista DM, Chuang H-H et al (2004) A local GABAergic system within rat trigeminal ganglion. Eur J Neurosci 23:745–757. https://doi.org/10.1111/j.1460-9568.2004.04020.x

Hendrikse ER, Bower RL, Hay DL, Walker CS (2019) Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia Int J Headache 39:403–419. https://doi.org/10.1177/0333102418765787

Holland PW, Hogan BL (1988) Spatially restricted patterns of expression of the homeobox-containing gene Hox 2.1. during mouse embryogenesis. Dev Camb Engl 102:159–174

Horgan K, van der Kooy D (1992) Visceral targets specify calcitonin gene-related peptide and substance P enrichment in trigeminal afferent projections. J Neurosci 12:1135–1143

Hou M, Kanje M, Longmore J et al (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 909:112–120

Hou M, Uddman R, Tajtj E, Edvinsson L (2003) Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res 964:179–186

Huang J, Lv Y, Fu Y et al (2015) Dynamic regulation of delta-opioid receptor in rat trigeminal ganglion neurons by lipopolysaccharide-induced acute pulpitis. J Endod 41:2014–2020. https://doi.org/10.1016/j.joen.2015.09.011

Ichikawa H, Schulz S, Höllt V, Sugimoto T (2003) The somatostatin sst2A receptor in the rat trigeminal ganglion. Neuroscience 120:807–813

Ichikawa H, Schulz S, Höllt V, Sugimoto T (2005) Delta-opioid receptor-immunoreactive neurons in the rat cranial sensory ganglia. Brain Res 1043:225–230. https://doi.org/10.1016/j.brainres.2005.02.041

Imboden H, Paul J, Nussberger J et al (2009) Endogenous angiotensinergic system in neurons of rat and human trigeminal ganglia. Regul Pept 154:23–31. https://doi.org/10.1016/j.regpep.2009.02.002

Jansen-Olesen I, Baun M, Amruttak DV et al (2014) PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides 48:53–64. https://doi.org/10.1016/j.npep.2014.01.004

Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain Lond Engl 6(Suppl A):61–68. https://doi.org/10.1006/ejpu.2001.0324

Jord E, Bautista DM, Chuang H-H et al (2004) Mustard oils and can-
Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators

Mason RT, Peterfreund RA, Sawchenko PE et al (1984) Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells. Nature 308:653–655

Mann RT, Peterfreund RA, Sawchenko PE et al (1984) Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells. Nature 308:653–655

Mayberg MR, Zervas NT, Moskowitz MA (1984) Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neuro 223:46–56. https://doi.org/10.1002/cne.902230105

Mclatchie LM, Fraser NJ, Main MJ et al (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333–339. https://doi.org/10.1038/20666

Mega S, Ray PR, Tavares-Ferreira D et al (2019) Differences between dorsal root and trigeminal ganglion nociceptors in mice revealed by translational profiling. J Neurosci 39:6829–6847. https://doi.org/10.1523/JNEUROSCI.2663-18.2019

Meng J, Osveidian SV, Wang J et al (2009) Activation of TRPV1 mediates calcitonin gene-related peptide peptide release, which excites trigeminal sensory neurons and is attenuated by a retracted botulinum toxin with anti-nociceptive potential. J Neurosci 29:4981–4992. https://doi.org/10.1523/JNEUROSCI.0494-09.2009

Miller S, Liu H, Warfvinge K et al (2016) Immunohistochemical localization of the calcitonin gene-related peptide binding site in the primates trigeminalovascular system using functional antagonist antibodies. Neuroscience 328:165–183. https://doi.org/10.1016/j.neuroscience.2016.04.046

Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43:S16–20

Nassini R, Materassi S, Vriens J et al (2012) The “headache tree” marker for chronic headache. Curr Pain Headache Rep 21:18. https://doi.org/10.1186/1471-2202-6-4

Neubert J, Matsuka Y, Maidment NT, Spigelman I (2002) Microdialysis in trigeminal ganglia. Brain Res Brain Res Protoc 10:102–108

O’Connor TP, van der Kooy D (1988) Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J Neurosci 8:2468–2476

Pavlović WI, Raible DW (2012) Specification of neural crest into sensory neuron and melanocyte lineages. Dev Biol 366:55–63. https://doi.org/10.1016/j.ydbio.2012.02.038

Philippidou P, Dassen JS (2013) Hox genes: choreographers in neural development, architects of circuit organization. Neuron 80:12–34. https://doi.org/10.1016/j.neuron.2013.09.020

Price TJ, Flores CM (2007) Critical evaluation of the colocalization of calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolecitin B4 binding in primary afferent neurons of the rat and mouse. J Pain 8:263–272. https://doi.org/10.1016/j.jpain.2006.09.005

Price TJ, Patwardhan A, Akopian AN et al (2004) Modulation of trigeminal sensory neuron activity by the dual cannabinoid-1 agonist agonist and antagonist, N-arachidonoyl-dopamine and arachidonyl-2-chloroethanamide. Br J Pharmacol 141:1118–1130. https://doi.org/10.1038/sj.bjp.0705711

Price TJ, Louria MD, Candelario-Soto D et al (2005) Treatment of trigeminal ganglion neurons in vitro with NGF, GDNF or BDNF: effects on neuronal survival, neurochemical properties and TRPV1-mediated neuropeptide secretion. BMC Neurosci 6:4. https://doi.org/10.1186/1471-2202-6-4

Quart M, Del Fiacco M (1994) Enkephalins occur and colocalize with substance P in human trigeminal ganglion neurons. NeuroReport 5:465–468

Quartu M, Serra MP, Ambu R et al (2002) AMPA-type glutamate receptor subunits 2/3 in the human trigeminal sensory ganglion and subnucleus caudalis from prenatal ages to adulthood. Mech Ageing Dev 123:463–471

Raisingshani M, Zhong L, Jeffry JA et al (2011) Activation characteristics of transient receptor potential ankyrin 1 and its role in nociception. Am J Physiol Cell Physiol 301:C587–600. https://doi.org/10.1152/ajpcell.00465.2010

Riesco N, Cernuda-Morollón E, Pascual J (2017) Neuropeptides as a marker for chronic headache. Curr Pain Headache Rep 21:18. https://doi.org/10.1186/s11916-017-0618-8

Rubio-Beltrán E, Correnti E, Deen M et al (2018) PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. https://doi.org/10.1186/s11199-018-1089-8

Russell FA, King R, Smillie S-J et al (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94:1099–1142. https://doi.org/10.1152/physrev.00034.2013

Russo AF (2015) Calcitonin gene-related peptide (CGRP). Annu Rev Pharmacol Toxicol 55:533–552. https://doi.org/10.1146/annurev-pharm-tox-010814-124701

Sahara Y, Noro N, Iida Y et al (1997) Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 17:6611–6620

Salas MM, Hargreaves KM, Akopian AN (2009) TRPA1-mediated responses in trigeminal sensory neurons: interaction between TRPA1 and TRPV1. Eur J Neurosci 29:1568–1578. https://doi.org/10.1111/j.1460-9568.2009.06702.x

Schueler M, Neuhuber WL, De Col R, Messlinger K (2014) Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents. Headache 54:996–1009. https://doi.org/10.1111/head.12371

Seiler K, Nusser JI, Lennerz JK et al (2013) Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment. J Headache Pain 14:74. https://doi.org/10.1186/1129-2377-14-74

Shelukhina I, Mikhailov N, Abushik P et al (2017) Cholinergic nociceptive mechanisms in rat meninges and trigeminal ganglia: potential implications for migraine pain. Front Neurol 8:163. https://doi.org/10.3389/fneur.2017.00163

Shinoda M, Kawashima K, Ozaki N et al (2007) P2X3 receptor mediates heat hyperalgesia in a rat model of trigeminal neuropathic pain. J Pain 8:588–597. https://doi.org/10.1016/j.jpain.2007.03.001

Simonietti M, Giniatullin R, Fabbretti E (2008) Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J Biol Chem 283:18743–18752. https://doi.org/10.1074/jbc.M800296200

Skingle M, Birch PJ, Leighton GE, Humphery PP (1990) Lack of antinociceptive activity of sumatriptan in rodents. Cephalalgia Int J Headache 10:207–212. https://doi.org/10.1046/j.1468-2982.1990.1005207.x

Souslova V, Cesare P, Ding Y et al (2000) Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 407:1015–1017. https://doi.org/10.1038/35039526

Spray DC, Iglesias R, Shaer N et al (2019) Gap junction mediated signaling between satellite glia and neurons in trigeminal ganglia. Glia 67:791–801. https://doi.org/10.1002/glia.23554

Staikopoulos V, Sessle BJ, Furness JB, Jennings EA (2007) Localization of P2X2 and P2X3 receptors in rat trigeminal ganglion neurons. Neuroscience 144:208–216. https://doi.org/10.1016/j.neuroscience.2006.09.035

Springer
Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181. https://doi.org/10.1038/sj.bjp.0705807

Suadicani SO, Cherkas PS, Zuckerman J et al (2010) Bidirectional calcium signaling between satellite glial cells and neurons in cultured mouse trigeminal ganglia. Neuron Glia Biol 6:43–51. https://doi.org/10.1017/S1740925X09990408

Suzuki H, Iwanaga T, Yoshie H et al (2002) Expression of galanin receptor-1 (GALR1) in the rat trigeminal ganglia and molar teeth. Neurosci Res 42:197–207

Tajti J, Uddman R, Möller S et al (1999) Messenger molecules and calcitonin gene-related peptide receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst 76:176–183

Tajti J, Szok D, Majláth Z et al (2015) Migraine and neuropeptides. Neuro peptides 52:29–30. https://doi.org/10.1016/j.npep.2015.03.061

Takeda M, Takahashi M, Matsumoto S (2012) Suppression of neurokinin-1 receptor in trigeminal ganglia attenuates central sensitization following inflammation. J Peripher Nerv Syst JPNS 17:169–181. https://doi.org/10.1111/j.1529-8027.2012.00404.x

Takshid MA, Owji AA, Panjehshahin MR (2007) In vitro effects of adrenomedullin and calcitonin gene-related peptide on the release of serotonin and amino acids from rat dorsal spinal cord. Neurosci Lett 420:193–197. https://doi.org/10.1016/j.neulet.2007.03.061

Teicher C, De Col R, Messlinger K (2017) Hydrogen sulfide mediating both excitatory and inhibitory effects in a rat model of meningeal nociception and headache generation. Front Neurol 8:336. https://doi.org/10.3389/fneur.2017.00336

Teixeira JM, Oliveira MCG, Nociti FH et al (2010) Involvement of temporomandibular joint P2X3 and P2X2/3 receptors in carrageenan-induced inflammatory hyperalgesia in rats. Eur J Pharmacol 645:79–85. https://doi.org/10.1016/j.ejphar.2010.06.008

Thalakoti S, Patil VV, Damodaram S et al (2007) Neuron-glial signaling in trigeminal ganglion: implications for migraine pathology. Headache 47:1008–1023. https://doi.org/10.1111/j.1526-4610.2007.00854.x (discussion 24–25)

Tzabazis A, Mechanic J, Miller J et al (2016) Oxytocin receptor expression in the trigeminal nociceptive system and potential role in the treatment of headache disorders. Cephalalgia Int J Headache 36:943–950. https://doi.org/10.1177/0333102416618165

Vause CV, Durham PL (2010) Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: findings from array analysis. Neurosci Lett 473:163–167. https://doi.org/10.1016/j.neulet.2010.01.074

Vedder H, Afrinster HU, Otten U (1993) Nerve growth factor (NGF) regulates tachykinin gene expression and biosynthesis in rat sensory neurons during early postnatal development. Neuropeptides 24:351–357

Villa G, Ceruti S, Zanardelli M et al (2010) Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus. Mol Pain 6:89. https://doi.org/10.1186/1744-8069-6-89

Viney TJ, Schmidt TW, Giersch W et al (2004) Regulation of the cell-specific calcitonin/calcitonin gene-related peptide enhancer by USF and the Foxa2 forkhead protein. J Biol Chem 279:49948–49955. https://doi.org/10.1074/jbc.M406659200

Walker CS, Eftekhami S, Bower RJ et al (2015) A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol 2:595–608. https://doi.org/10.1002/acn3.197

Walker CS, Raddant AC, Woollery MJ et al (2017) CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured. Cephalalgia Int J Headache. https://doi.org/10.1177/03331024176911762

Wang X, Hu R, Liang J et al (2016) 5-HT7 Receptors are not involved in neuropeptide release in primary cultured rat trigeminal ganglion neurons. J Mol Neurosci 59:251–259. https://doi.org/10.1007/s12031-016-0727-6

Weick M, Cherkas PS, Härtig W et al (2003) P2 receptors in satellite glial cells in trigeminal ganglia of mice. Neuroscience 120:969–977

Wiesenfeld-Hallin Z, Hökfelt T, Lundberg JM et al (1984) Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat. Neurosci Lett 52:199–204

Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat–intravital microscope studies. Cephalalgia Int J Headache 17:525–531. https://doi.org/10.1046/j.1468-2982.1997.1704525.x

Wu L, Zhang H, Liao L et al (2013) Trigeminal ganglion morphology in human fetus. Microsc Res Tech 76:598–605. https://doi.org/10.1002/jemt.22204

Xiang Z, Bo X, Burnstock G (1998) Localization of ATP-gated P2X receptor immunoreactivity in rat sensory and sympathetic ganglia. Neurosci Lett 256:105–108

Yang J, Wei X, Bischoff C et al (2013) pH-evoked dural afferent signaling is mediated by ASIC3 and is sensitized by mast cell mediators. Headache 53:1250–1261. https://doi.org/10.1111/head.12152

Yang Z, Wang Y, Luo W et al (2009) Trigeminal expression of N-methyl-D-aspartate receptor subunit 1 and behavior responses to experimental tooth movement in rats. Angle Orthod 79:951–957. https://doi.org/10.2319/082308-444.1

Ye Z, Wimalawansa SJ, Westlund KN (1999) Receptor for calcitonin gene-related peptide: localization in the dorsal and ventral spinal cord. Neuroscience 92:1389–1397. https://doi.org/10.1016/S0306-4522(99)00088-3

Young RF, Stevens R (1979) Unmyelinated axons in the trigeminal motor root of human and cat. J Comp Neurol 183:205–214. https://doi.org/10.1002/cne.901830114

Zhang Z, Winborn CS, Marquez de Prado B, Russo AF (2007) Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27:2693–2703. https://doi.org/10.1523/JNEUROSCI.4542-06.2007

Zhao B, Wang H-B, Lu Y-J et al (2011) Transport of receptors, receptor immunoreactivity in rat sensory and sympathetic ganglia. Neuroscience 177:169–181. https://doi.org/10.1016/j.neuroscience.2011.03.002

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.